Selected article for: "acute hospital and admission time"
Author: Andersen, Kathleen M; Mehta, Hemalkumar B; Palamuttam, Natasha; Ford, Daniel; Garibaldi, Brian T; Auwaerter, Paul G; Segal, Jodi; Alexander, G Caleb
Title: Association Between Chronic Use of Immunosuppresive Drugs and Clinical Outcomes From Coronavirus Disease 2019 (COVID-19) Hospitalization: A Retrospective Cohort Study in a Large US Health System
  • Cord-id: uk6wch0x
  • Document date: 2021_1_7
    • ID: uk6wch0x
    Snippet: BACKGROUND: It is unclear whether chronic use of immunosuppressive drugs worsens or improves the severity of coronavirus disease 2019 (COVID-19), with plausible mechanisms for both. METHODS: Retrospective cohort study in 2121 consecutive adults with acute inpatient hospital admission between 4 March and 29 August 2020 with confirmed or suspected COVID-19 in a large academic health system, with adjustment for confounding with propensity score–derived stabilized inverse probability of treatment
    Document: BACKGROUND: It is unclear whether chronic use of immunosuppressive drugs worsens or improves the severity of coronavirus disease 2019 (COVID-19), with plausible mechanisms for both. METHODS: Retrospective cohort study in 2121 consecutive adults with acute inpatient hospital admission between 4 March and 29 August 2020 with confirmed or suspected COVID-19 in a large academic health system, with adjustment for confounding with propensity score–derived stabilized inverse probability of treatment weights. Chronic immunosuppression was defined as prescriptions for immunosuppressive drugs current at the time of admission. Outcomes included mechanical ventilation, in-hospital mortality, and length of stay. RESULTS: There were 2121 patients admitted with laboratory-confirmed (1967, 93%) or suspected (154, 7%) COVID-19 during the study period, with a median age of 55 years (interquartile range, 40–67). Of these, 108 (5%) were classified as immunosuppressed before COVID-19, primarily with prednisone (>7.5 mg/day), tacrolimus, or mycophenolate mofetil. Among the entire cohort, 311 (15%) received mechanical ventilation; the median (interquartile range) length of stay was 5.2 (2.5–10.6) days, and 1927 (91%) survived to discharge. After adjustment, there were no significant differences in the risk of mechanical ventilation (hazard ratio [HR], .79; 95% confidence interval [CI], .46–1.35), in-hospital mortality (HR, .66; 95% CI, .28–1.55), or length of stay (HR, 1.16; 95% CI, .92–1.47) among individuals with immunosuppression and counterparts. CONCLUSIONS: Chronic use of immunosuppressive drugs was neither associated with worse nor better clinical outcomes among adults hospitalized with COVID-19 in one US health system.

    Search related documents:
    Co phrase search for related documents
    • academic health system and adjusted mortality: 1, 2, 3
    • academic health system and admission prior: 1
    • acute respiratory syndrome and additionally control: 1, 2
    • acute respiratory syndrome and adjusted mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adjusted mortality odd: 1
    • acute respiratory syndrome and adjusted mortality odd ratio: 1
    • acute respiratory syndrome and admission date: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and admission distribution: 1, 2, 3, 4, 5
    • acute respiratory syndrome and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and long term morbidity: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and low high albumin: 1, 2, 3, 4, 5
    • adjust mortality and admission prior: 1
    • adjusted mortality and admission date: 1, 2, 3
    • adjusted mortality and admission prior: 1, 2, 3, 4, 5, 6, 7
    • admission distribution and low high albumin: 1, 2
    • admission prior and long term morbidity: 1